ArticlePathology oncology research : POR2002
Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen- and progesterone-receptor dependent and associated with poor prognostic factors.
Article in Pathology oncology research : POR, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- Prognostic influences of B-cell lymphoma 2-positive expression on late recurrence in breast cancer.Annals of surgical treatment and research · 2023Article
- Alterations in mRNA profiles of trastuzumab‑resistant Her‑2‑positive breast cancer.Molecular medicine reports · 2018Article
- BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database.Cancer research and treatment · 2018Article
- BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer.Journal of breast cancer · 2016Article
- Discovery of a new method for potent drug development using power function of stoichiometry of homomeric biocomplexes or biological nanomotors.Expert opinion on drug delivery · 2016Article
- New approach to develop ultra-high inhibitory drug using the power function of the stoichiometry of the targeted nanomachine or biocomplex.Nanomedicine (London, England) · 2015Article
- BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasion.Experimental cell research · 2015Article
- Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin?PloS one · 2013Article
- Heterogeneity of Bcl-2 expression in metastatic breast carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2010Article
- Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?Diagnostic pathology · 2006Article
- Classification of ductal carcinoma in situ by gene expression profiling.Breast cancer research : BCR · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In normal breast, Bcl2 is expressed in the non-pregnant and non-involuting mammary epithelium. The exact mechanism and the effect of the down regulation of the Bcl2 expression on breast cancer cells are not clearly defined. We compared down regulation as well as the persistent expression of Bcl2 with ER, PR, p53, and c-erb-B2 overexpression and clinicopathologic variables, and tumor stage in 11 cases of ductal carcinomas in situ (DCIS) and 44 cases of invasive ductal carcinomas (IDC) of Korean women by immunohistochemical studies. Bcl2 down regulation was found in 39% of IDC and in 18% of DCIS cases. In IDC, while persistent Bcl2 expression was displayed in 95% and 78.9% of ER and PR immunoreactive ones and 71.9 % of c-erb-B2 immunonegative ones. Seventeen cases of Bcl2 down regulated IDC had a significant correlation with ER negativity (94.1%), PR negativity, (76.5%), and high nuclear (61.1% is grade III) and histological grade (76% is grade III). However, in DCIS, no significant correlation between the Bcl2 expression and various parameters were obtained, probably due to small sample size. In conclusion, the Bcl2 expression was both ER and PR dependent and down regulation of Bcl2 in IDC was significantly correlated with poor prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.